Obesity - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Obesity Market Outlook

Thelansis's "Obesity Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Obesity treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Obesity Overview

Obesity is a complex, chronic disease characterized by excessive accumulation of body fat that impairs health and increases the risk of multiple comorbidities, including type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders. It arises from an interplay of genetic, environmental, behavioral, and metabolic factors, with energy imbalance-calories consumed exceeding calories expended-being the central driver.

Diagnosis is typically based on body mass index (BMI ≥30 kg/m2), though additional measures such as waist circumference and body composition provide better insight into cardiometabolic risk. Beyond physical health, obesity is also associated with reduced quality of life, psychological distress, and social stigma.

The disease is increasingly recognized as a biologically regulated, chronic condition, requiring long-term management. Treatment approaches are multifaceted and include:

• Lifestyle modification and nutritional counseling
• Physical activity and behavioral therapy
• Pharmacotherapy
• Bariatric surgery in severe cases

Recent therapeutic advancements-particularly GLP-1 and dual incretin-based therapies-have significantly improved clinical outcomes, enabling sustained weight loss and transforming the treatment paradigm. Despite these advances, obesity remains a major global public health challenge, requiring scalable prevention strategies and personalized long-term care models.

Key Highlights

• The diagnosed obesity population in Germany is projected to grow significantly, increasing from 7.2 million in 2025 to 14.2 million by 2035, reflecting a high growth trajectory (7% CAGR).
• Obesity represents a high-prevalence, high-burden disease, with substantial long-term healthcare costs driven by associated comorbidities.
• Despite large patient numbers, treatment penetration remains low, with many patients managed primarily through lifestyle interventions.

Market Overview

• The obesity market is undergoing rapid expansion, driven by high-efficacy therapies and increasing treatment uptake.
• The obesity market in France is projected to grow from $410M in 2025 to $1.57Bn by 2035, reflecting a strong CAGR of 14-15%.
• The diagnosed population in Germany is expected to grow at ~7% CAGR, significantly expanding the addressable market.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Hanmi Pharmaceutical Company Limited
• Tonghua Dongbao Pharmaceutical Co.,Ltd
• Aphaia Pharma US LLC
• NeuroBiogen Co., Ltd
• Eli Lilly and Company
• MindRank AI Ltd
• Pfizer
• Kailera
• Glyscend, Inc.
• NodThera Limited
• Palatin Technologies, Inc
• BrightGene Bio-Medical Technology Co., Ltd.
• Aardvark Therapeutics, Inc.
• Alnylam Pharmaceuticals
• Guangdong Raynovent Biotech Co., Ltd
• Innovent Biologics (Suzhou) Co. Ltd.
• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
• Fujian Shengdi Pharmaceutical Co., Ltd.
• Arrowhead Pharmaceuticals
• Hudson Biotech
• Zomagen Biosciences Ltd.
• Corxel Pharmaceuticals
• Regeneron Pharmaceuticals
• Regor Pharmaceuticals Inc.
• Boehringer Ingelheim
• Novo Nordisk A/S
• Skye Bioscience, Inc.
• Shionogi
• Amgen
• Rhythm Pharmaceuticals, Inc.
• Vanda Pharmaceuticals
• Kallyope Inc.
• Metsera, a wholly owned subsidiary of Pfizer
• S1 Biopharma, Inc.
• Biophytis
• AstraZeneca
• Shandong Suncadia Medicine Co., Ltd.
• Biohaven Therapeutics Ltd.
• Beijing QL Biopharmaceutical Co.,Ltd
• Rose Pharma Inc
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Vincentage Pharma Co., Ltd
• CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
• Gan and Lee Pharmaceuticals, USA
• Verdiva Bio Dev Limited
• Gan & Lee Pharmaceuticals.
• Carmot Therapeutics, Inc.
• Exerkine Corporation
• Terns, Inc.
• Chendu DIAO Pharmaceutical Group CO., LTD.
• Hangzhou Sciwind Biosciences Co., Ltd.
• The United Bio-Technology (Hengqin) Co., Ltd.
• Scholar Rock, Inc.
• Biomed Industries, Inc.
• Ikaria Bioscience Pty Ltd
• Hoffmann-La Roche
• HK inno.N Corporation
• Actimed Therapeutics Ltd
• Inversago Pharma Inc.
• Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.
• Immunwork, Inc.
• Veru Inc.
• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
• Neuraly, Inc.
• ARKAY Therapeutics